---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-035924"
form_type: "8-K"
ticker: null
cik: "0001463361"
company_name: "Unity Biotechnology, Inc."
filed_at: "2025-03-10T23:59:59+00:00"
generated_at: "2026-05-25T01:08:06.689392+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# UNITY appoints Bausch + Lomb R&D chief Yehia Hashad to board; advances UBX1325

## Summary
- Dr. Yehia Hashad, EVP R&D and CMO at Bausch + Lomb, joins board effective March 8, 2025.
- Hashad also appointed to Science Committee; receives 20,000-share option grant (3-yr vest) + $45k annual cash retainer.
- CEO cites Hashad's expertise as UNITY prepares for Phase 2b ASPIRE 24-week data readout for UBX1325 in DME.
- Hashad brings 25+ years in ophthalmology and retinal drug development, including leadership at Allergan and Novartis.
- Board chairman notes Hashad's strategic perspective will help advance UBX1325 and pipeline.

## SEC filing metadata
- accession: 0000950170-25-035924
- form_type: 8-K
- cik: 0001463361
- company_name: Unity Biotechnology, Inc.
- filed_at: 2025-03-10T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1463361/000095017025035924/0000950170-25-035924-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1463361/000095017025035924/ubx-20250308.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-035924
- JSON: https://secwatch.observer/filing/0000950170-25-035924.json
- Plain text: https://secwatch.observer/filing/0000950170-25-035924.txt

## Key facts
- Executive change
  Yehia Hashad was appointed as Director at Unity Biotechnology, Inc..
  - Action: appointed
  - Role: Director
  source text: On March 8, 2025, the Board of Directors (the “Board”) of UNITY Biotechnology, Inc. (“Unity” or the “Company”) appointed Dr. Yehia Hashad, M.D., current executive vice president of research & development and chief medical officer at Bausch + Lomb, to the Board and as a member of the Science Committee, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1463361/000095017025035924/0000950170-25-035924-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.